HERV targeted CAR-T therapy for RCC / Adagene, National Heart, Lung, and Blood Institute - LARVOL DELTA

Novel Targets, Approaches, and Observations from Cancer Patients Treated with TCR and CAR Gene Modified T Cells (CIMT 2025) - "We have conducted Phase I clinical trials where melanoma and renal cell carcinoma patients were infused with autologous TIL 1383I or HERV-E TCR T cells respectively or NHL patients were infused with autologous CD19 CAR T cells...The problem is that no one approach to reactivate the T cells is effective in all patients pointing to the complexity and redundancy in mechanisms the hosts have for suppressing the host anti-tumor immune response. Therefore, a more detailed analysis of the patients with interesting clinical and biological responses will be necessary to better understand how to improve the outcomes for patients treated with gene modified T cells."

Clinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD34

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health (GlobeNewswire) - "Adagene...today announced the successful completion of its component of the collaboration with Richard Childs, M.D., Chief of the Laboratory of Transplantation Immunotherapy at the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH). As a result of the collaboration, Adagene discovered antibodies that Dr. Child’s laboratory has turned into a CAR-T cell therapy candidate for the potential treatment of renal cell carcinoma...'I look forward to the evaluation and hopefully the development of this novel CAR-T cell and other antibody-based therapies in clinical trials'...The NIH will lead and be responsible for the manufacturing and clinical development of the CAR-T cell therapy candidate."

Licensing / partnership • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma